Approval · Notice of Compliance 36541 · 2025
BAMBEVI: Notice of Compliance 36541
Issued December 12, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36541
- Date
- December 12, 2025
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to the drug product and drug substance manufacturing process
- Canadian reference product
- AVASTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BAMBEVI | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 100 MG per 4ML
- BEVACIZUMAB 400 MG per 16ML